Navigation Links
Closer Analysis Shows Consumer Groups Make Gains in Stem Cell Patent Challenges Against WARF; Appeal Still Planned Against Narrowed Claims

SANTA MONICA, Calif., Feb. 28 /PRNewswire-USNewswire/ -- Closer analysis of the patent office "non-final" decision on a human embryonic stem cell patent held by the Wisconsin Alumni Research Foundation (WARF) shows the following gains made for researchers:

-- The original broad patent was abandoned showing it was underserved and new amended claims have been narrowed.

-- The original patent covered all embryonic stem cells no matter how they are derived, but the amended "non-final" ruling, while permitting the patent, narrowed the claim only to stems cells derived from pre-implantation embryos.

-- The newest stem cell research technology -- Induced Pluripotent Stem Cells (IPS cells) -- would clearly not be covered by the narrowed patent.

-- Stem cells derived from fetal tissue could have been claimed under the old patent, but now cannot be.

Consumer groups still believe the narrowed patent is invalid and should be revoked. They intend to challenge the latest patent office decision.

The challenge brought by the Foundation for Taxpayer and Consumer Rights (FTCR) and the Public Patent Foundation (PUBPAT) already produced a major victory for consumers and researchers when WARF announced in January 2007 that it was substantially easing its licensing requirements on stem cells. The groups filed re-examination requests on three patents, the '913, '806 and '780 in July 2006.

"We've made progress in thwarting WARF's overreaching patents and changing the organization's aggressive behavior toward the research community," said John M. Simpson, FTCR Stem Cell Project Director. "We are in this for the long haul."

The groups said they would appeal any later final decision by the examiner supporting the amended claims to the Patent and Trademark Office's Board of Appeals, which frequently overturns the decision made by examiners. The groups also have the right to appeal any decision of that board to the U.S. Circuit Court for the Federal Circuit, if necessary.

The "non-final office decision" in the inter partes re-examination of the '913 patent was posted late Wednesday on the PTO's website.

"The examiner based his decision on his own belief that it would not have been obvious to isolate human stem cells using widely known methods to isolate mouse stem cells, which contradicts the sworn testimony that we provided of four renowned stem cell embryologists who were doing such work," said Dan Ravicher, PUBPAT Executive Director. "Thus, the examiner took his own opinion over the opinions of our four leading stem cell scientist witnesses."

Joining the two consumer groups in the challenge from the beginning was Dr. Jeanne Loring, now of the Scripps Institute. After the initial rejection, Dr. Alan Trounson, then of Australia's Monash University and now president of the California Institute for Regenerative Medicine, Dr. Douglas Melton of Harvard and Dr. Chad Cowan of Harvard filed affidavits supporting the challenge.

"WARF executives were acting like arrogant bullies blinded by dollar signs," said Simpson. "Our challenge has engendered a more co-operative stance on their part."

Decisions are pending on the '780 and '806 patents. No other country recognizes the three WARF patents.

The Foundation for Taxpayer and Consumer Rights is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at:

The Public Patent Foundation is a not-for-profit legal services organization that represents the public's interests against the harms caused by the patent system, particularly the harms caused by wrongly issued patents and unsound patent policy. For more information, visit us on the web at

SOURCE Foundation for Taxpayer and Consumer Rights
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UBs bioblower closer to protecting soldiers from biological attack
2. Bug guts map brings scientists closer to understanding different bugs role in the body
3. Study Gets Closer to Origins of Leukemia
4. Research Gets Closer to Origin of Parkinsons Disease
5. UGA researchers 1 step closer to elusive cancer vaccine
6. HASP Online Provides Free Job Safety Analysis Tool Available Online
7. Doing Angioplasty Long After Heart Attack Still Worth It, Analysis Shows
8. By color-coding atoms, new Cornell electron microscope promises big advance in materials analysis
9. Global Analysis of Human DNA Tracks Migration, Identity
10. DNA Analysis Could Help Customize Treatments for MS
11. Congressional Budget Office Analysis of HR971 Rejects Pharmacy Benefit Managers Bogus Claim Bill Would Cost $29 Billion Over 5 Years
Post Your Comments:
(Date:6/27/2016)... Lafayette, California (PRWEB) , ... ... ... a pioneer in the patient payment industry today announced its strategic partnership ... and health system workflows. , The two companies’ proven, proprietary technology combine ...
(Date:6/26/2016)... ... ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect Plugin ... whole new perspective by using the title layers in ProSlice Levels to split-up ... Levels contains over 30 Different presets to choose from. FCPX users can ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... PARK RIDGE, Ill. and INDIANAPOLIS ... caliber of students receiving a Lilly Diabetes Tomorrow,s Leaders ... hands. The 2016 scholarship winners, announced today online at ... refused to let type 1 diabetes stand in the ... Lilly Diabetes has supported the Foundation,s scholarship program since ...
(Date:6/23/2016)... , June 23, 2016 The vast majority ... outpatient dialysis facility.  Treatments are usually 3 times a ... per visit, including travel time, equipment preparation and wait ... but especially grueling for patients who are elderly and ... skilled nursing and rehabilitation centers for some duration of ...
Breaking Medicine Technology: